Biotech

Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials -- Gilead Sciences, Inc. and Eisai Co., Ltd. today announced that the Japanese Ministry of Health, Labour and Welfare has granted Gilead K.K. regulatory approval of Jyseleca ® a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis in patients who have had an inadequate ...

-- Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile Through 52 Weeks in Clinical Trials --

Gilead Sciences, Inc. (Nasdaq: GILD) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca ® (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005942/en/

Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. The companies will jointly commercialize the medicine to make it available to physicians and patients across Japan.

"Despite progress in the treatment of RA, existing therapies have not enabled many patients to reach the treatment goals recommended in clinical guidelines. There continues to be a need for effective and well-tolerated new treatment options," said Tsutomu Takeuchi, MD, Professor of Internal Medicine and Chief of Rheumatology at the School of Medicine, Keio University. "Jyseleca is a new JAK inhibitor that, in clinical trials, has demonstrated clinical improvement, low disease activity and clinical remission in a broad patient population, including patients with inadequate response to biologics."

"RA causes many patients debilitating fatigue and pain that can significantly interfere with their daily lives," said Yoshiya Tanaka, MD, Professor at First Department of Internal Medicine, University of Occupational and Environmental Health. "It is important to have new treatment options that can offer patients effective symptom control and bring them new hope."

The approval in Japan is based on robust clinical trial results from the global FINCH Phase 3 and DARWIN Phase 2 programs. The FINCH and DARWIN programs evaluated Jyseleca in more than 3,500 patients across a range of RA patient populations, including patients new to treatment and those who have demonstrated inadequate response to treatment with standard of care including biologic DMARDs. Patients receiving Jyseleca once daily showed improvements in clinical signs and symptoms, decreases in disease activity, and less progression of structural damage in their joints. Across the FINCH trials, Jyseleca demonstrated a consistent safety profile, and the frequency of adverse events of interest (including serious infections, herpes zoster, venous thromboembolism and major cardiovascular events) was comparable to control groups.

Across the FINCH and DARWIN trials, the most common adverse reactions were nausea, upper respiratory tract infection, urinary tract infection and dizziness. Rates of herpes zoster and pneumonia were 0.2 percent and 0.3 percent, respectively. The exposure adjusted incidence rate of serious infections per 100 persons per year (95 percent CI) was 1.7 percent (1.3, 2.1) in the Jyseleca 200 mg group and 2.5 percent (1.9, 3.3) in the Jyseleca 100 mg group, respectively. When prescribing Jyseleca, physicians are advised to monitor patients for the development of new, or exacerbation of existing, serious infections including pneumonia, tuberculosis, sepsis and other viral infections.

"This regulatory approval recognizes the benefit that Jyseleca may be able to provide people living with RA who have not been successfully treated with prior therapies and represents an important advance in the treatment of this challenging disease," said Luc Hermans, MD, President and Representative Director, Gilead Sciences, K.K.

"Now that Jyseleca has received approval in Japan, we look forward to leveraging our extensive experience in clinical development and commercialization in the RA area in Japan to bring this new treatment option to patients across Japan as soon as possible, and contribute to the improvement of patients' quality of life," said Hidenori Yabune, President of Eisai Japan, Senior Vice President, Eisai.

Gilead is developing Jyseleca in collaboration with Galapagos NV (Mechelen, Belgium (Nasdaq and EuroNext: GLPG)). The two companies are conducting global studies investigating the potential role of Jyseleca in a variety of diseases, including the previously reported Phase 3 SELECTION trial in ulcerative colitis.

About the FINCH Program

The FINCH Phase 3 program investigated the efficacy and safety of filgotinib 100 mg and 200 mg once-daily, in RA patient populations ranging from early stage to biologic-experienced patients. FINCH 1 was a 52-week, randomized, placebo- and adalimumab-controlled trial in combination with MTX, enrolling 1,759 adult patients with moderately to severely active RA who had inadequate response to MTX. The primary endpoint in FINCH 1 was ACR20 at Week 12. The trial included radiographic assessment at Weeks 24 and 52. FINCH 2 was a global, 24-week randomized, double-blind, placebo-controlled, Phase 3 study evaluating filgotinib on a background of conventional synthetic disease-modifying anti-rheumatic drug(s) (csDMARDs) among 449 adult patients with moderately to severely active RA who had not adequately responded to biologic DMARDs (bDMARDs). The primary endpoint in FINCH 2 was ACR20 at Week 12. FINCH 3 was a 52-week, randomized trial in 1,252 MTX-naïve patients to evaluate filgotinib 200 mg alone and filgotinib 100 mg or 200 mg combined with MTX versus MTX alone. The primary endpoint in FINCH 3 was ACR20 at Week 24. The trial included radiographic assessment at Weeks 24 and 52.

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company's website at www.gilead.com .

For more information on Gilead Sciences K.K., please visit the company's website at https://www.gilead.co.jp/ .

About Eisai Co., Ltd.

Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care ( hhc ) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com .

Gilead Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that Jyseleca may not be successfully commercialized for the treatment of rheumatoid arthritis in Japan. There is also the possibility of unfavorable results from ongoing and additional clinical trials involving Jyseleca and the risk that other regulatory authorities may not approve Jyseleca for the treatment of rheumatoid arthritis and other indications, and any marketing approvals, if granted, may have significant limitations on its use. Further, it is possible that Gilead may make a strategic decision to discontinue development and commercialization of Jyseleca, and as a result, Jyseleca may never be successfully commercialized. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Jyseleca ® , Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc. or its related companies.

Gilead
Douglas Maffei, PhD, Investors
+1 (650) 522-2739

Ken Takashima, Media - Japan
+81-3-6745-0850

Arran Attridge, Media - US
+1 (650) 425-8975

Eisai
Investor Relations
+81-3-3817-3016

Public Relations
+81-3-3817-5120

News Provided by Business Wire via QuoteMedia

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECHTM-processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other disease states beyond hypertension where it has already shown tremendous promise

Keep reading... Show less
Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

Lexaria's DehydraTECH-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2

(TheNewswire)

Lexaria Bioscience Corp.

Results suggest broader applications for DehydraTECH-CBD beyond hypertension

Keep reading... Show less
BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

BioHarvest Sciences Inc. Produces Significant Amount of Cannabis Without Growing the Cannabis Plant

  • Cannabis produced has a Trichomes density of up to 200 times greater than in a plant-grown product while solving major industry challenges of consistency, safety, and environmental sustainability
  • The Company is ready to engage with key players in the global Cannabis industry

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or the "Company") has announced that it has produced a meaningful amount (10 kilograms) of full-spectrum Cannabis biomass at a commercial scale without growing the plant itself. (For full illustration, watch the "Cannabis Without Plants - History in the Making" video at https:youtu.beNAurl6oa1xo)

Keep reading... Show less
Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. Announces Participation in the Benzinga Global Small Cap Conference

Lexaria Bioscience Corp. (NASDAQ: LEXX) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space.

Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/.

Keep reading... Show less

Amgen Announces New Data Being Presented At ASH 2021

- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63 rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia and virtually, from Dec. 11-14, 2021 .

"The data being presented at ASH demonstrates Amgen's commitment to reaching more patients with our innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers," said David M. Reese , M.D., executive vice president of Research and Development at Amgen. "By accelerating the development and delivery of transformative medicines in difficult to treat and vulnerable patient populations, including children and pregnant women, we continue to focus on the relentless pursuit of breakthroughs for blood cancer patients and their families."

Keep reading... Show less

Upadacitinib Achieved Primary and Key Secondary Endpoints in First Phase 3 Induction Study in Patients with Crohn's Disease

ABBVie (NYSE: ABBV) today announced positive top-line results from U-EXCEED, a Phase 3 induction study, showing upadacitinib (45 mg once daily) achieved both primary endpoints of clinical remission a,b and endoscopic response c at week 12. 1 The U-EXCEED study enrolled patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to biologic therapy, with over 60 percent having previously failed two or more biologics. 1 U-EXCEED is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe Crohn's disease. 1

"The data from this first Phase 3 induction study in Crohn's disease suggest upadacitinib may help address the needs of patients suffering from this disease, as demonstrated in stringent endpoints such as endoscopic response," said Michael Severino , M.D., vice chairman and president, AbbVie. "We continue to leverage our expertise in IBD by driving research and development that help shape the IBD landscape and elevate standards of care for patients."

Keep reading... Show less

Top News

Related News